Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
暂无分享,去创建一个
K. Watson | E. Barrett-Connor | R. Goldberg | M. Temprosa | R. Ratner | S. Rajpathak | J. Crandall | K. Mather | Sandra T. Foo
[1] E. Barrett-Connor,et al. Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS) , 2017, Diabetic medicine : a journal of the British Diabetic Association.
[2] V. Jamdade,et al. Statin use and the risk of developing diabetes: a network meta‐analysis , 2016, Pharmacoepidemiology and drug safety.
[3] S. Tsimikas,et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. , 2015, Atherosclerosis.
[4] D. Waters,et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. , 2015, Journal of the American College of Cardiology.
[5] J. Shaikh,et al. Statin Use And Risk Of Developing Diabetes In Cardiovascular Disease: Systematic Literature Review And Meta-Analysis. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] G. Bray,et al. Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS) , 2014, Diabetes.
[7] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.
[8] M. Quon,et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. , 2012, Atherosclerosis.
[9] J. Manson,et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.
[10] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .
[11] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[12] P. Barter,et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.
[13] G. Guyatt,et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.
[14] J. Liao,et al. Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[15] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[16] C. White,et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. , 2010, Diabetes research and clinical practice.
[17] David M Nathan,et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.
[18] Paul M. Ridker,et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.
[19] Marinella Temprosa,et al. Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. , 2009, American journal of hypertension.
[20] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[21] H. Shimano,et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. , 2006, Journal of atherosclerosis and thrombosis.
[22] M. Nakata,et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.
[23] S. Fowler,et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. , 2005, Diabetes.
[24] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[25] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[26] B. Ahrén,et al. Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. , 2002, Diabetes.
[27] L. Chamberlain. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes , 2001, FEBS letters.
[28] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[29] Helen Brown,et al. Applied Mixed Models in Medicine , 2000, Technometrics.
[30] Fujimoto,et al. The Diabetes Prevention Program Baseline characteristics of the randomized cohort , 2000 .
[31] C. Champagne,et al. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. , 2000, Diabetes care.
[32] C. Bogardus,et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.
[33] M. Nakata,et al. Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells , 1999, British journal of pharmacology.
[34] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.